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Abstract
Background: Hepatic embryonal sarcoma (HES) is a rare but aggressive primary tumor of the
liver occurring most frequently in childhood.
Case presentation: We report a case of a 52 year old woman having previously undergone
treatment for ovarian serous papillary carcinoma who subsequently presented with a large solitary
mass in the liver. Initially this was presumed to be metastasis from the ovarian primary however,
on further examination it was shown to be a primary hepatic embryonal sarcoma.
Conclusion: Primary liver tumors should be considered in differential diagnoses in patients with
ovarian cancer who subsequently present with liver tumors. This is particularly important when
there is no direct evidence of recurrence of ovarian cancer.
Background
Hepatic embryonal sarcoma (HES) is rare primary tumor
of the liver usually occurring in childhood. It is generally
considered an aggressive tumor with a poor prognosis.
Approximately 60 cases have been reported in adults. On
the contrary, ovarian carcinoma frequently tends to
metastasize to the liver [1]. We report a case of a woman
who had previously undergone treatment for bilateral
ovarian serous papillary carcinoma and subsequently pre-
sented with a large solitary mass in the liver which turned
out to be a primary hepatic embryonal sarcoma. We also
review the current literature, diagnosis and treatment of
HES.
Case presentation
A 52 year old woman presented with pain and a palpable
mass in the right upper quadrant of the abdomen 18
months after completing treatment for ovarian carci-
noma. She had previously undergone bilateral salpingo-
oophorectomy and en bloc subtotal colectomy for bilateral
high-grade ovarian serous papillary carcinoma infiltrating
the sigmoid colon. She also had peritoneal and diaphrag-
matic seedlings which were debulked concurrently. After
the resection, the residual disease was estimated to be less
than 0.5 cm2. Subsequently, she received 6 cycles of adju-
vant chemotherapy with carboplatin and taxol. Her
CA125 level which was elevated at 149 U/L prior to resec-
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tion later returned to 8 U/L (normal range = 0 – 25 U/L).
Apart from chemotherapy, there was no past history of
exposure to radiotherapy or any carcinogens.
During this presentation, the only abnormality on routine
hematology and biochemistry was a slightly elevated alka-
line phosphatase at 178 U/L (normal range = 35–130 U/
L). The CA125 level was within the reference range (7 U/
L) and no other tumor markers were assayed. A Compu-
terized Tomography (CT) scan revealed a large heteroge-
neous mass almost completely replacing the right lobe of
the liver (Figure 1). No other abdominal, pelvic or lung
lesions were identified. Due to the recent history of ovar-
ian cancer, this lesion was suspected to be a solitary met-
astatic deposit from the ovarian cancer. The liver lesion
was not biopsied in order to avoid any needle tract seed-
ing with malignant cells. In the absence of any extrahe-
patic disease she proceeded to undergo an extended right
hepatectomy. During hepatectomy the tumor was found
to be adherent to the diaphragm, a part of which was
removed en bloc. Post-operatively, she made a good recov-
ery without any complications.
Macroscopically, the tumor was a large, solid and cystic
mass that included areas of necrosis and cystic degenera-
tion measuring 18 × 12 × 8 cm (Figure 2). Microscopi-
cally, it consisted of pleomorphic malignant spindle cells
including rhabdoid and bizarre giant cell forms on a
chrondromyxoid stromal background (Figure 3) with
focal Periodic Acid Schiff-positive cytoplasmic granules.
There was no evidence of epithelial differentiation which
excluded the possibility of sarcomatoid hepatocellular
carcinoma. Immunohistochemical staining was positive
for alpha1-antitrypsin but showed no other indicators of
differentiation. This contrasted with the serous papillary
morphology of the previously resected ovarian tumor that
showed no sarcomatoid areas and no rhabdoid differenti-
ation. The liver tumor was therefore judged to be a second
primary rather than a metastatic deposit of the resected
ovarian carcinoma. The lesion was classified as primary
HES on the basis of its morphology and immunohisto-
Computerized Tomography scan of the abdomen, the tumor  is shown to be occupying almost the whole the right lobe of  the liver Figure 1
Computerized Tomography scan of the abdomen, 
the tumor is shown to be occupying almost the 
whole the right lobe of the liver.
Cut section of the resected hepatic tumor Figure 2
Cut section of the resected hepatic tumor.
Representative section of a more cellular area showing  plump spindle cells, bizarre giant cell forms and scattered  apoptotic bodies Figure 3
Representative section of a more cellular area show-
ing plump spindle cells, bizarre giant cell forms and 
scattered apoptotic bodies. (Haematoxylin and eosin 
stain, photographed at ×200 magnification).World Journal of Surgical Oncology 2009, 7:55 http://www.wjso.com/content/7/1/55
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chemical staining pattern with complete excision noted at
the hepatic resection margins.
After remaining well for approximately 6 months she
developed progressive shortness of breath and a follow-up
CT scan demonstrated a large recurrent tumor contiguous
across the right hemithorax and abdomen. A percutane-
ous biopsy of this mass confirmed the recurrence of the
primary hepatic sarcoma. Palliative chemotherapy with
ifosfamide and doxorubicin was commenced but had to
be stopped after 3 cycles due to severe side effects. She
received palliative care for gradual deterioration and died
6 months later.
Discussion
Ovarian cancer usually presents with widespread intra-
peritoneal metastasis [2]. A minority of patients present
with aggressive disease manifested by liver, lung or brain
metastases [3]. An autopsy study of 428 patients with
ovarian cancer reported that over 40% of the patients with
ovarian cancer had evidence of liver metastases at the time
of death [1]. Amongst the ovarian cancers, the stromal
tumors were the most likely histological subtype to metas-
tasize to the liver [1].
Approximately 20% of the patients with epithelial type of
ovarian cancer have been reported to have normal levels
of CA125 [4,5]. During second presentation of this
patient, the liver function tests were slightly deranged but
the CA125 level was within the reference range.
Primary liver sarcomas are rare tumors and represent only
0.2% of all primary liver tumors [6]. This group includes
a number of different histological types such as angiosar-
coma, leiomysarcoma, fibrosarcoma, HES, and malignant
fibrous histiocytoma [7]. HES are most commonly
reported in a pediatric age group, with the peak incidence
between the ages of 6 and 10 years. Only 68 cases have
been reported in the adult population [8]. Although the
etiology of primary liver sarcomas is unclear, there is an
increased risk associated with radiation therapy and high
doses of alkylators or anthracyclines [8]. The use of Thoro-
trast as a radiological contrast medium in the 1950s was
associated with a very high incidence of hepatic angiocsar-
comas [9]. Our patient had received taxol and carboplatin
as adjuvant chemotherapy after resection of ovarian can-
cer but there is no documented association of these agents
with development of primary liver sarcomas.
The presentation of liver sarcomas is usually non-specific
with symptoms such as abdominal discomfort, anorexia,
fever or weight loss [10]. Hepatomegaly may be present
with large tumors and liver function tests may be
deranged although frank jaundice is rare [7,10]. The non-
specific nature of the presenting symptoms makes clinical
diagnosis extremely difficult without imaging or biopsy.
Although the lesion can be identified on ultrasonography
and CT scan, contrast-enhanced Magnetic Resonance
Imaging (MRI) scan is the best imaging modality for char-
acterization of primary liver tumors [11].
There are a number of radiographic features which distin-
guish HES from mesenchymal and other primary hepatic
tumors. The myxoid stroma typical of HES appear as large
central areas of hypointense signal on T1-weighted images
that have high intensity signal on T2-weighted images.
Similarly, in the solid peripheral areas of the mass hetero-
geneous contrast enhancement is seen on both CT and
MRI scans [12].
HES have previously been associated with poor outcome.
In 1978 Stocker reported a series of 31 patients with HES
with mean survival of less that one year after diagnosis
[10]. Although radical surgery remains the mainstay of
treatment, recent studies have shown improved survival
with radical surgery and use of ifosfamide-based multi-
agent chemotherapy. Almogy et al reported on a series of
8 primary liver sarcomas including two HES managed
with surgical resection and adjuvant chemotherapy [13].
Following a liver resection, one patient with a satellite
lesion and a second patient with recurrent HES were
treated with chemotherapy which led to tumor shrinkage
and enabled a second hepatic resection. There is mount-
ing evidence to suggest that neo-adjuvant chemotherapy
would allow down-sizing of HES to be followed by resec-
tional surgery [14,15]. Bisogno et al identified 17 children
with HES treated with initial conservative surgery and
multi-agent chemotherapy followed by second-look sur-
gery for any residual disease [14]. They report 70% (12/
17) survival at follow up (ranging from 2.4 to 20 years).
Thus, in most cases, the accepted standard treatment
would consist of aggressive surgical resection with combi-
nation chemotherapy either in neoadjuvant or adjuvant
setting.
Conclusion
In this patient HES masqueraded as a metastatic ovarian
carcinoma. This case illustrates that the possibility of a pri-
mary liver tumor should be considered in patients with
ovarian cancer who subsequently present with liver
tumors, particularly when there is no direct evidence of
recurrence of ovarian cancer.
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